MedTrace Logo

Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old

NCT02035696 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 671

Last updated 2018-07-10

Study results available
· View outcomes & findings →

Summary

To evaluate the safety and immunogenicity of four influenza vaccines in children 6 months to \< 48 months of age

Conditions

Interventions

BIOLOGICAL

Trivalent influenza vaccine (TIVc)

BIOLOGICAL

Trivalent influenza vaccine-licensed

Licensed influenza vaccine

Sponsors & Collaborators

  • Novartis Vaccines

    collaborator INDUSTRY

  • Seqirus

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
6 Months
Max Age
48 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2014-06-30
Completion
2014-12-31

Countries

  • United States
  • Finland
  • Philippines
  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02035696 on ClinicalTrials.gov